Exelon COO logs stock awards, sale in Form 4
Exelon Corporation executive Michael Innocenzo, EVP & Chief Operating Officer, reported multiple equity compensation transactions dated 02/02/2026.
Rhea-AI Filing Summary
Exelon Corporation executive Michael Innocenzo, EVP & Chief Operating Officer, reported multiple equity compensation transactions dated 02/02/2026. Several batches of restricted stock units and performance shares were converted into Exelon common stock, increasing his directly held common shares to 86,802, plus 2,835 shares in an employee stock purchase plan.
He also received a new grant of 20,668 2026 restricted stock units and held 2,274 deferred phantom share equivalents as of 12/31/2025. To cover tax obligations on vesting, 9,547 shares of common stock were withheld at $43.91 per share, and he disposed of an additional 7,199 shares at the same price.
Positive
- None.
Negative
- None.
Insider Trade Summary
27,469 shares exercised/converted
Exercise
14 txns
Insider
Innocenzo Michael
Role
EVP & Chief Operating Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | 2023 Restricted Stock Units | 2,432 | $0.00 | $0.00 |
| Exercise | 2024 Restricted Stock Units | 5,748 | $0.00 | $0.00 |
| Exercise | 2025 Restricted Stock Units | 7,734 | $0.00 | $0.00 |
| Grant/Award | 2026 Restricted Stock Units | 20,668 | $0.00 | $0.00 |
| Grant/Award | 2023-2025 Performance Shares | 11,555 | $0.00 | $0.00 |
| Exercise | 2023-2025 Performance Shares | 11,555 | $0.00 | $0.00 |
| Exercise | Common Stock | 2,432 | $0.00 | $0.00 |
| Exercise | Common Stock | 5,748 | $0.00 | $0.00 |
| Exercise | Common Stock | 7,734 | $0.00 | $0.00 |
| Exercise | Common Stock | 11,555 | $0.00 | $0.00 |
| Exercise Price or Tax Liability | Common Stock | 9,547 | $43.91 | $419K |
| Disposition | Common Stock | 7,199 | $43.91 | $316K |
| holding | Deferred phantom share equivalents | -- | -- | -- |
| holding | Common Stock ESPP | -- | -- | -- |
Holdings After Transaction:
2023 Restricted Stock Units — 0 contracts (Direct);
2024 Restricted Stock Units — 5,746 contracts (Direct);
2025 Restricted Stock Units — 15,466 contracts (Direct);
2026 Restricted Stock Units — 20,668 contracts (Direct);
2023-2025 Performance Shares — 0 contracts (Direct);
Common Stock — 86,802 shares (Direct);
Deferred phantom share equivalents — 2,274 contracts (Direct);
Common Stock ESPP — 2,835 shares (Direct)
Footnotes (7)
- F1. Restricted stock unit (RSU) award granted under the Exelon Long Term Incentive Plan (LTIP). Award vests in 1/3 increments at the January or February meeting of the Exelon Talent Management and Compensation Committee (TMCC) with each RSU representing the right to receive one share of Exelon common stock upon vesting. The award accrues additional RSUs each quarter through automatic dividend reinvestment, and the additional RSUs vest on the same schedule as the underlying award.
- F2. Performance share award granted under the LTIP for the three-year performance period referenced in Column 1 based upon the TMCC's determination of performance achieved for the period. Each performance share represents the right to receive one share or the cash equivalent of one share pursuant to the LTIP's terms with respect to individual stock ownership levels. Performance share awards vest immediately on their grant date.
- F3. Balance at the time of this vesting includes 87 additional shares acquired through automatic dividend reinvestment during 2025.
- F4. Balance at the time of this vesting includes 412 additional shares acquired through automatic dividend reinvestment during 2025.
- F5. Balance at the time of this vesting includes 831 additional shares acquired through automatic dividend reinvestment during 2025.
- F6. Phantom share equivalents held in the reporting person's Exelon stock fund account that is part of a multi-fund, non-qualified deferred compensation plan. The stock fund is a unitized fund that consists of both Exelon common stock and short-term liquid investments. Units of the fund are acquired through quarter-end contributions and dividend reinvestment and will be settled for cash upon the termination of the reporting person. The balance of phantom share equivalents may fluctuate due to changes in the value of the fund units.
- F7. Balance as of 12/31/2025 and includes 79 phantom share equivalents accrued during 2025 through automatic dividend reinvestment.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did Exelon (EXC) COO Michael Innocenzo report?
Michael Innocenzo reported vesting and conversion of multiple restricted stock unit and performance share awards into Exelon common stock on 02/02/2026. He also received a new 2026 RSU grant, had tax-withholding share disposals, and sold additional shares at a stated market price.
What equity awards vested or were exercised for Exelon COO Michael Innocenzo?
2023, 2024, and 2025 restricted stock units and 2023-2025 performance shares were involved in transactions coded “M” on 02/02/2026. These derivative awards converted into Exelon common stock, with remaining unvested RSU balances still reported as directly owned derivative securities.
What new Exelon equity awards did the COO receive in this filing?
On 02/02/2026, Michael Innocenzo was granted 20,668 2026 Restricted Stock Units under Exelon’s Long Term Incentive Plan. These RSUs entitle him to receive an equal number of Exelon common shares upon vesting, according to the vesting schedule described in the plan footnotes.
AI-generated analysis. How Rhea-AI works. Not financial advice.
